Last reviewed · How we verify

NCT04116736

ACUVUE® OASYS With Transitions™ Light Intelligent Technology™ Clinical Performance Registry

Completed Results posted Last updated 23 May 2025
What this trial tests

trial testing ACUVUE® OASYS with Transitions™ in Vision Satisfaction in Bright Light in 146 participants. Completed in 10 March 2023.

Timeline
19 October 2019
Primary endpoint
10 March 2023
10 March 2023

Quick facts

Lead sponsorJohnson & Johnson Vision Care, Inc.
StatusCompleted
Study typeOBSERVATIONAL
Enrollment146
Start date19 October 2019
Primary completion10 March 2023
Estimated completion10 March 2023
Sites22 locations across United Kingdom, Spain

Drugs / interventions tested

Conditions studied

Sponsor

Johnson & Johnson Vision Care, Inc. — full company profile →

Who can join

18 and older, any sex, with Vision Satisfaction in Bright Light. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Vision Satisfaction in Bright Lighting - 2-Week Questionnaire Primary · 2-week questionnaire follow-up

Subjects will be asked to evaluate their vision satisfaction in bright lighting by rating their level of agreement with the statement "I am satisfied with the quality of my vision in bright lighting with these contact lenses" using a 5-point agreement Likert scale (Strongly Disagree, Disagree, Neither Agree Nor Disagree, Agree, and Strongly Agree). In the Control group 4 subjects were identified as ineligible after the screening visit because they were wearing ineligible Control lenses. Therefore, only 54 subjects were included in the Control group for the primary endpoint data summary. The nu

Strongly Agree
GroupValue95% CI
Test33
Control21
Agree
GroupValue95% CI
Test33
Control24
Neither Agree Nor Disagree
GroupValue95% CI
Test10
Control2
Disagree
GroupValue95% CI
Test2
Control0
Strongly Disagree
GroupValue95% CI
Test0
Control0
Missing Response (Subject didn't answer the item)
GroupValue95% CI
Test10
Control7
Vision Satisfaction in Bright Lighting - 4-Month Questionnaire Primary · 4-month questionnaire follow-up

Subjects will be asked to evaluate their vision satisfaction in bright lighting by rating their level of agreement with the statement "I am satisfied with the quality of my vision in bright lighting with these contact lenses" using a 5-point agreement Likert scale (Strongly Disagree, Disagree, Neither Agree Nor Disagree, Agree, and Strongly Agree). In the Control group 4 subjects were identified as ineligible after the screening visit because they were wearing ineligible Control lenses. Therefore, only 54 subjects were included in the Control group for the primary endpoint data summary. The nu

Strongly Agree
GroupValue95% CI
Test24
Control20
Agree
GroupValue95% CI
Test38
Control25
Neither Agree Nor Disagree
GroupValue95% CI
Test7
Control2
Disagree
GroupValue95% CI
Test2
Control0
Strongly Disagree
GroupValue95% CI
Test0
Control0
Missing Response (Subject didn't answer the item)
GroupValue95% CI
Test17
Control7
Vision Satisfaction in Bright Lighting - 12-Month Questionnaire Primary · 12-month questionnaire follow-up

Subjects will be asked to evaluate their vision satisfaction in bright lighting by rating their level of agreement with the statement "I am satisfied with the quality of my vision in bright lighting with these contact lenses" using a 5-point agreement Likert scale (Strongly Disagree, Disagree, Neither Agree Nor Disagree, Agree, and Strongly Agree). In the Control group 4 subjects were identified as ineligible after the screening visit because they were wearing ineligible Control lenses. Therefore, only 54 subjects were included in the Control group for the primary endpoint data summary.

Strongly Agree
GroupValue95% CI
Test23
Control22
Agree
GroupValue95% CI
Test29
Control21
Neither Agree Nor Disagree
GroupValue95% CI
Test4
Control2
Disagree
GroupValue95% CI
Test3
Control0
Strongly Disagree
GroupValue95% CI
Test0
Control0
Missing Response (Subject didn't answer the item)
GroupValue95% CI
Test29
Control9
Overall Quality of Vision - 2-Week Questionnaire Secondary · 2-week questionnaire follow-up

Overall quality of vision was assessed subjectively using the item "I am satisfied with the overall quality of my vision with these contact lenses". The item used a 5-point agreement scale: Strongly Disagree, Disagree, Neither Agree Nor Disagree, Agree, and Strongly Agree. In the Control group 4 subjects were identified as ineligible after the screening visit because they were wearing ineligible Control lenses. Therefore, only 54 subjects were included in the Control group for this secondary endpoint data summary. The number of missing responses in each lens group was reported.

Strongly Agree
GroupValue95% CI
Test37
Control27
Agree
GroupValue95% CI
Test36
Control20
Neither Agree Nor Disagree
GroupValue95% CI
Test3
Control0
Disagree
GroupValue95% CI
Test1
Control0
Strongly Disagree
GroupValue95% CI
Test0
Control0
Missing Response (Subject didn't answer the item)
GroupValue95% CI
Test11
Control7
Overall Quality of Vision - 4-Month Questionnaire Secondary · 4-month questionnaire follow-up

Overall quality of vision was assessed subjectively using the item "I am satisfied with the overall quality of my vision with these contact lenses". The item used a 5-point agreement scale: Strongly Disagree, Disagree, Neither Agree Nor Disagree, Agree, and Strongly Agree. In the Control group 4 subjects were identified as ineligible after the screening visit because they were wearing ineligible Control lenses. Therefore, only 54 subjects were included in the Control group for this secondary endpoint data summary. The number of missing responses in each lens group was reported.

Strongly Agree
GroupValue95% CI
Test31
Control22
Agree
GroupValue95% CI
Test35
Control23
Neither Agree Nor Disagree
GroupValue95% CI
Test5
Control2
Disagree
GroupValue95% CI
Test0
Control0
Strongly Disagree
GroupValue95% CI
Test0
Control0
Missing Response (Subject didn't answer the item)
GroupValue95% CI
Test17
Control7
Overall Quality of Vision - 12-Month Questionnaire Secondary · 12-month questionnaire follow-up

Overall quality of vision was assessed subjectively using the item "I am satisfied with the overall quality of my vision with these contact lenses". The item used a 5-point agreement scale: Strongly Disagree, Disagree, Neither Agree Nor Disagree, Agree, and Strongly Agree. In the Control group 4 subjects were identified as ineligible after the screening visit because they were wearing ineligible Control lenses. Therefore, only 54 subjects were included in the Control group for this secondary endpoint data summary. The number of missing responses in each lens group was reported.

Strongly Agree
GroupValue95% CI
Test25
Control18
Agree
GroupValue95% CI
Test30
Control25
Neither Agree Nor Disagree
GroupValue95% CI
Test1
Control2
Disagree
GroupValue95% CI
Test3
Control0
Strongly Disagree
GroupValue95% CI
Test0
Control0
Missing Response (Subject didn't answer the item)
GroupValue95% CI
Test29
Control9
Overall Comfort - 2-Week Questionnaire Secondary · 2-week questionnaire follow-up

Overall comfort was assessed using the item "How would you rate the overall comfort of these contact lenses?". The item used the 5-point excellence scale, Excellent, Very Good, Good, Fair, and Poor. In the Control group 4 subjects were identified as ineligible after the screening visit because they were wearing ineligible Control lenses. Therefore, only 54 subjects were included in the Control group for this secondary endpoint data summary. The number of missing responses in each lens group was reported.

Excellent
GroupValue95% CI
Test19
Control9
Very Good
GroupValue95% CI
Test37
Control28
Good
GroupValue95% CI
Test17
Control9
Fair
GroupValue95% CI
Test4
Control1
Poor
GroupValue95% CI
Test0
Control0
Missing Response (Subject didn't answer the item)
GroupValue95% CI
Test11
Control7
Overall Comfort - 4-Month Questionnaire Secondary · 4-month questionnaire follow-up

Overall comfort was assessed using the item "How would you rate the overall comfort of these contact lenses?". The item used the 5-point excellence scale, Excellent, Very Good, Good, Fair, and Poor. In the Control group 4 subjects were identified as ineligible after the screening visit because they were wearing ineligible Control lenses. Therefore, only 54 subjects were included in the Control group for this secondary endpoint data summary. The number of missing responses in each lens group was reported.

Excellent
GroupValue95% CI
Test27
Control16
Very Good
GroupValue95% CI
Test25
Control19
Good
GroupValue95% CI
Test12
Control9
Fair
GroupValue95% CI
Test6
Control2
Poor
GroupValue95% CI
Test1
Control1
Missing Response (Subject didn't answer the item)
GroupValue95% CI
Test17
Control7
Overall Comfort - 12-Month Questionnaire Secondary · 12-month questionnaire follow-up

Overall comfort was assessed using the item "How would you rate the overall comfort of these contact lenses?". The item used the 5-point excellence scale, Excellent, Very Good, Good, Fair, and Poor. In the Control group 4 subjects were identified as ineligible after the screening visit because they were wearing ineligible Control lenses. Therefore, only 54 subjects were included in the Control group for this secondary endpoint data summary. The number of missing responses in each lens group was reported.

Excellent
GroupValue95% CI
Test20
Control10
Very Good
GroupValue95% CI
Test28
Control23
Good
GroupValue95% CI
Test8
Control9
Fair
GroupValue95% CI
Test2
Control2
Poor
GroupValue95% CI
Test1
Control1
Missing Response (Subject didn't answer the item)
GroupValue95% CI
Test29
Control9
Pulfrich Effect Secondary · 2-week, 4-month, and 12-month questionnaire follow-up

Pulfrich effect was assessed subjectively using the item "While wearing these lenses, my depth perception of moving objects has NOT been impacted". Subjects who disagreed or strongly disagreed with the statement were considered to have experienced the Pulfrich effect. In the Control group 4 subjects were identified as ineligible after the screening visit because they were wearing ineligible Control lenses. Therefore, only 54 subjects were included in the Control group for this secondary endpoint data summary.

Number of Subjects Experienced the Pulfrich Effect at Least Once
GroupValue95% CI
Test4
Control1
Number of Subjects Experienced the Pulfrich Effect at 2-Week Evaluation
GroupValue95% CI
Test4
Control0
Number of Subjects Experienced the Pulfrich Effect at 4-Month Evaluation
GroupValue95% CI
Test0
Control1
Number of Subjects Experienced the Pulfrich Effect at 12-Month Evaluation
GroupValue95% CI
Test0
Control0
Serious or Significant Adverse Events Secondary · Throughout the duration of the study, up to 12 months

A serious adverse event is any untoward medical occurrence that is potentially sight-threatening, requires hospitalization, results in persistent or significant disability / incapacity, or requires intervention to prevent permanent damage. Significant adverse events are usually symptomatic and warrant discontinuation (temporary or permanent) of the test article (excluding serious adverse events).

GroupValue95% CI
Test0
Control0

Sponsor's own description

This registry study is a one-year, one-visit, observational, prospective, open-label, two-arm, multi-center, multi-national, post-market study of approximately 300 patients who have recently been fitted with the ACUVUE® OASYS with Transitions™ and approximately 300 patients who have recently been fitted with spherical nonphotochromic reusable marketed silicone hydrogel contact lenses (of any brand). Eligible subjects will be asked to complete a Patient Registration Questionnaire several times throughout the year.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of ACUVUE® OASYS with Transitions™

Trials testing the same drug.

Other Johnson & Johnson Vision Care, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04116736.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing